Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 16/20 | 0.56 |
| ▸ | KDM6B | O15054 | 8/20 | 0.56 |
| ▸ | KDM4D | Q6B0I6 | 6/20 | 0.52 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | KDM4A | O75164 | 2/20 | 0.48 |
| ▸ | KDM5C | P41229 | 1/20 | 0.47 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178702 | 0.82 | GPR35 (0.58) | GPR35KDM4E | |
| SCHEMBL6997874 | 0.80 | GPR35 (0.63) | GPR35AKR1B1KDM4E | |
| SCHEMBL7991807 | 0.79 | KDM4C (0.64) | KDM4CKDM6BKDM4DEGLN3KDM5A | |
| SCHEMBL4439968 | 0.76 | KDM4C (0.69) | KDM4CKDM6BKDM4DEGLN3KDM5A | |
| SCHEMBL4254113 | 0.75 | TSHR (0.43) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL17621616 | 0.75 | MAPT (0.61) | GPR35KDM4E | |
| SCHEMBL3730911 | 0.74 | KDM4C (0.62) | KDM4CKDM6BKDM4DEGLN3KDM5A | |
| SCHEMBL15295150 | 0.74 | TP53 (0.54) | KDM4CKDM6BKDM4E | |
| SCHEMBL11534363 | 0.74 | MAPT (0.66) | GPR35 | |
| SCHEMBL10719056 | 0.74 | KDM4C (0.77) | KDM4CKDM6BKDM4DKDM5BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9212149-B2 | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-1740551-B9 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1740551-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-6225329-B1 | USEFUL IN THE TREATMENT OF TYPE I DIABETES, TYPE II DIABETES, IMPAIRED GLUCOSE TOLERANCE, INSULIN AUTOIMMUNITY DISEASES WITH DYSFUNCTIONS OF THE COAGULATION SYSTEM, ALLERGIC DISEASES | NOVO NORDISK A/S (DK) | 2001-05-01 | — | — | US | disclosed |
| EP-1080068-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | Novo Nordisk A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| EP-1062199-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046237-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046236-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | MMP13, MMP14, MMP25 | KDM4C 1024/4885KDM6B 1013/4885KDM4D 606/4885 |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | KDM4C 1435/4885KDM6B 737/4885KDM4D 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.